Answers are grounded in this paper and cite their sources.
From September 2014 to April 2015, 6 persons who had occupational exposures to Zaire ebolavirus in West Africa received investigational agent rVSV-ZEBOV or TKM-100802 for postexposure prophylaxis and were monitored in the United States. All patients experienced self-limited symptoms after postexposure prophylaxis; none developed Ebola virus disease.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: